Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress.
Individuals can access the conference call by dialing:
US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297
Live audio of the webcast will be available online on the Investor Relations page of the Company's website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investor Relations page at investors.standardbio.com.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.Patent and License Information: standardbio.com/legal/notices.©2025 Standard BioTools Inc. All rights reserved.
Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.
Investor Contact:David Holmesir@standardbio.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Genetic Testing Market Research 2025: Genetic Discoveries Creating New Diagnostic Markets
Discover opportunities and pitfalls in the booming Genetic Testing industry, driven by advances in genetics and lower costs. Explore breakthroughs in Predictive Diagnostics, Pharmacogenomic Testing, and Direct-to-Consumer models across 14 countries and 5 regions. Get insights and forecasts to guide informed investment decisions. Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Genetic Testing Markets. Global Market Analysis with Forecasts by Applications, Technologies, Products and Users with Executive and Consultant Guides" has been added to offering. The genetic testing industry is experiencing unprecedented growth, with its potential proving boundless as it expands across various sectors. This growth is being propelled by advancements in our understanding of the genetic basis of health and disease, coupled with decreasing costs. These factors are causing a surge in demand and development within the genetic testing market, presenting both opportunities and challenges. The industry's expansion is significantly influenced by the increasing realization that specific genetic profiles are crucial for the efficacy of novel therapies. Pharmacogenomics is establishing a foothold, underscoring the necessity for genetic testing to tailor drug therapies to individual genetic compositions. As this field grows, it fosters an increasing array of tests, boosting the volume of the traditional genetic testing market and its scope, while also introducing new complexities. The report examines these trends, providing detailed analyses across 14 countries and five regions. It highlights predictive diagnostics, pharmacogenomic testing, and the burgeoning direct-to-consumer segment, offering insights into the technology underpinning the industry. By doing so, it demystifies the complexities, presenting clear information on industry dynamics, opportunities, and challenges. With this comprehensive understanding, stakeholders can anticipate growth patterns and market forecasts over the next five years. The insights provided arm industry experts, investors, and decision-makers with the necessary knowledge to make informed investment decisions and valuations. In a rapidly evolving market, staying informed with the latest data is essential for maintaining a competitive advantage. Key Topics Covered: 1 Market Guides1.1 Genetic Testing - Strategic Situation Analysis & Company Rankings1.2 Guide for Executives, Marketing, Sales and Business Development Staff1.3 Guide for Management Consultants and Investment Advisors 2 Introduction and Market Definition 2.1 Genetic Testing Definition in This Report 2.2 The Genomics Revolution2.3 Market Definition2.4 Methodology2.5 Perspective: Healthcare and the IVD Industry2.6 Chromosomes, Genes and Epigenetics 3 Market Overview 3.1 Players in a Dynamic Market3.2 Genetic Tests - Types, Examples and Discussion3.3 Industry Structure 4 Market Trends4.1 Factors Driving Growth 4.1.1 Genetic Discoveries Creating New Diagnostic Markets4.1.2 The Aging Effect4.1.3 Pharmacogenomics Drives Further Growth4.1.4 Oncology and Liquid Biopsy Enter New Era4.1.5 Fertility Practice Growth drives market4.1.6 Direct to Consumer begins to break out 4.2 Factors Limiting Growth4.2.1 Increased Competition Lowers Price 4.2.2 Lower Costs4.2.3 Testing usage analysis curtailing growth 4.2.4 Wellness has a downside4.3 Instrumentation, Automation and Diagnostic Trends4.3.1 Traditional Automation and Centralization 4.3.2 The New Automation, Decentralization and Point of Care 4.3.3 Instruments Key to Market Share4.3.4 Bioinformatics Plays a Role 4.3.5 PCR Takes Command 4.3.6 Next Generation Sequencing Fuels a Revolution 4.3.7 NGS Impact on Pricing4.3.8 Whole Genome Sequencing, A Brave New World4.3.9 Companion Diagnostics Blurs Diagnosis and Treatment 4.3.10 Shifting Role of Diagnostics 5 Genetic Testing Recent Developments5.1 Recent Developments5.1.1 Importance of This Section 5.1.2 How to Use This Section 5.2 Novitas Rescinds Coverage for Multiple Genetic Tests5.3 PerkinElmer (now Revvity) Becomes Dx Life Science Firm 5.4 New POC Genotyping Tests Based on Electromagnetic Detection 5.5 GenoMe Dx Launching dPCR Cancer Test 5.6 mDetect To Trial Breast Cancer Liquid Biopsy5.7 Genomics England, Aims to Sequence 100K Newborns 5.8 Juno Diagnostics NIPT With At-Home Sample Collection 5.9 Cardio Diagnostics Launches Genetic Cario Risk Test 5.10 Universal Genetic Testing in Breast Cancer Further Supported5.11 Aniling Gets CE-IVD Marks for Cancer Sequencing Tests 5.12 MyOme Lands Investment for WGS5.13 Type 2 Diabetes GWAS Enables Risk Prediction 5.14 LetsGetChecked to Acquire Veritas Genetics 5.15 Guardant Health Plans New Comprehensive Assay 5.16 Tesis Labs Raises $20M 5.17 Sema4: Sema4 Elements 5.18 Clarified Precision Medicine Acquires Interpares Biomedicine5.19 Genetic Technologies to Acquire DTC Genetic Test Provider EasyDNA 5.20 Illumina, Belgium Genetic Centers Partner on WGS-Based Dx5.21 NIH, Genomics England Launch Sequencing Studies Using Nanopore Technology5.22 Progenity Revenues Fall on COVID-19 Effect 5.23 Natera Launches Tumor Genomic Profiling Assay5.24 23andMe To Go Public5.25 Guardant Health to Offer Tumor Tissue Sequencing 5.26 Ancestry Quits Health Offering5.27 DTC Firm MyDNA Merges With Gene by Gene 5.28 Aetna Coverage for NIPT to Include All Pregnancies5.29 Agios Pharmaceuticals, PerkinElmer Partner on Hereditary Anemia Genetic Testing5.30 Tumor, Germline Testing of Cancer Patients Can Give Discordant Results 6 Profiles of Key Companies6.1 10x Genomics, Inc. 6.2 23andME Inc.6.3 Abbott Laboratories 6.4 Adaptive Biotechnologies 6.5 Admera Health, LLC6.6 Agilent/Dako6.7 Akonni Biosystems6.8 Amoy Diagnostics Co., Ltd. 6.9 LLC6.10 Anchor Dx 6.11 Arc Bio 6.12 Arrayit Corporation 6.13 ARUP Laboratories6.14 Aus Diagnostics6.15 BaseClear 6.16 Baylor Miraca Genetics Laboratories 6.17 Beckman Coulter Diagnostics 6.18 Becton, Dickinson and Company 6.19 BGI Genomics Co. Ltd 6.20 Bioarray Genetics 6.21 Biocept, Inc. 6.22 Biodesix Inc. 6.23 BioFluidica 6.24 BioGenex 6.25 Biolidics Ltd6.26 bioMerieux Diagnostics6.27 Bioneer Corporation6.28 Bio-Rad Laboratories, Inc6.29 Bio-Techne6.30 C2i Genomics 6.31 CareDx 6.32 Caris Molecular Diagnostics6.33 CellMax Life 6.34 Centogene 6.35 Cepheid (Danaher) 6.36 Circulogene 6.37 Clinical Genomics6.38 Color Genomics 6.39 Complete Genomics, Inc. - A BGI Company 6.40 CosmosID 6.41 Dante Labs.6.42 Datar Cancer Genetics Limited 6.43 Diasorin S.p.A. 6.44 Element Biosciences6.45 Element Biosciences6.46 Epic Sciences6.47 Epigenomics AG.6.48 Eurofins Scientific 6.49 Excellerate Bioscience 6.50 Fabric Genomics 6.51 Freenome 6.52 Fujirebio 6.53 Fulgent Genetics 6.54 Gene by Gene, Ltd. 6.55 Genedrive 6.56 GeneFirst Ltd.6.57 Genetron Holdings 6.58 Genomics England 6.59 Genomics Personalized Health (GPH)6.60 GenomOncology 6.61 Genzyme Corporation 6.62 Grifols 6.63 Guardant Health 6.64 Guardiome 6.65 HeiScreen 6.66 Helix 6.67 Helix OpCo6.68 Helomics6.69 Hologic 6.70 HTG Molecular Diagnostics 6.71 Human Longevity, Inc. 6.72 iCellate 6.73 Illumina 6.74 Incell Dx 6.75 Inivata 6.76 Integrated Diagnostics6.77 Invitae Corporation 6.78 Invivoscribe 6.79 Karius 6.80 Letsgetchecked 6.81 Lunglife AI Inc 6.82 Macrogen 6.83 MDNA Life SCIENCES, Inc.6.84 MDx Health 6.85 Medgenome6.86 Menarini Silicon Biosystems 6.87 Meridian Bioscience 6.88 Mesa Biotech (Thermo Fisher) 6.89 Mesa Laboratories, Inc. 6.90 Metabiomics Corp 6.91 miR Scientific 6.92 MNG Labs 6.93 NantHealth, Inc. 6.94 Natera 6.95 Nebula Genomics6.96 NeoGenomics 6.97 New England Biolabs, Inc. 6.98 NGeneBio6.99 Novogene Bioinformatics Technology Co., Ltd.6.100 Omega Bioservices 6.101 Oncocyte6.102 OncoDNA 6.103 OpGen 6.104 ORIG3N, Inc. 6.105 Origene Technologies 6.106 Oxford Nanopore Technologies 6.107 Pacific Biosciences 6.108 Panagene 6.109 PathoQuest S.A. 6.110 Perkin Elmer (now Revvity) 6.111 Personal Genome Diagnostics6.112 Personalis.6.113 Precipio 6.114 PrecisionMed6.115 Promega 6.116 Protagen Diagnostics 6.117 Qiagen 6.118 QuantuMDx 6.119 Roche Molecular Diagnostics 6.120 Roswell Biotechnologies 6.121 Seegene6.122 Sema4 Holdings6.123 6.124 Siemens Healthineers 6.125 simfo GmbH 6.126 Singlera Genomics Inc.6.127 Singular Genomics 6.128 SkylineDx 6.129 Standard BioTools 6.130 Sure Genomics, Inc. 6.131 Sysmex 6.132 Sysmex Inostics6.133 Tempus Labs, Inc. 6.134 Thermo Fisher Scientific Inc. 6.135 Ultima Genomics 6.136 Ultima Genomics 6.137 Variantyx 6.138 Vela Diagnostics 6.139 Volition 6.140 Vyant Bio 6.141 Zymo Research Corp 7 Global Market Size7.1 Global Market by Country7.2 Global Market by Application7.3 Global Market by Technology7.4 Global Market by Product7.5 Global Market by User 8 Market Sizes by Application8.1 Newborn Testing Market8.2 NIPT Market8.3 Predictive Testing Market8.4 Oncology Testing Market8.5 DTC Testing Market8.6 Other Testing Market 9 Global Genetic Testing Market by Technology9.1 PCR Testing Market9.2 NGS Market9.3 Cytogenetic Testing Market9.4 Other Testing Market 10 Global Genetic Testing Market by Product10.1 Instruments Market10.2 Reagents and Kits Market10.3 Software Market10.4 Services Market 11 Global Genetic Testing Market by User11.1 Academic Market11.2 Clinical Market11.3 Pharmaceutical Market11.4 Industrial and Other Market 12 The Future of Genetic Testing 13 Appendices13.1 United States Medicare System: Laboratory Fees Schedule13.2 The Most Used IVD Assays 13.3 The Highest Grossing Assays For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
Single Cell Genomics Market Research 2025: Immuno-oncology, Research Range, Technology Maturity & Convergence, Declining Costs Bolster Growth
Discover the potential of Single Cell Genomics in our latest report. As it revolutionizes healthcare, identify opportunities, growth expectations, and market potential. Stay ahead with insights into this booming field that is redefining genomics and biotechnology. Ideal for management teams. Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Single Cell Genomics Markets: Forecasts by Analyte, Product, Workflow, User, Application and Country with Executive and Consultant Guides" has been added to offering. The market for SCG is experiencing a notable surge as it opens new doors in understanding the genomics of individual cells. This leap forward in biotechnology not only inspires fresh discoveries but also enhances our approach to personalized medicine and precision healthcare. Key stakeholders in the healthcare and biotechnology industries should take note of the opportunities SCG presents, from improving patient outcomes to developing innovative therapeutic strategies. This report is designed to equip management teams with insights into the pivotal developments in SCG, including technological advancements and the accompanying strategic opportunities. As the SCG technology outpaces current market expectations, it's crucial for business leaders to stay informed about the potential opportunities and pitfalls that accompany this rapid evolution. The report sheds light on growth expectations, possible market size, and the interplay between genomics, immunology, and SCG, aiding readers in making informed strategic decisions. Single Cell Genomics (SCG) is revolutionizing the scientific research and development landscape, offering transformative insights across healthcare and biotechnology sectors. This digital press release outlines the findings of a comprehensive new report exploring whether SCG could potentially replace traditional genomics. The implications of SCG are vast, with applications extending from identifying novel life forms to uncovering new diseases and pioneering cures. As the technology continues to evolve, its footprint in clinical applications is expanding, driving substantial market growth. As SCG continues to transition from laboratory research to practical clinical applications, understanding its potential impact on the market becomes increasingly important. This press release invites stakeholders to delve into the report for a thorough analysis of the technological trajectory, market dynamics, and future prospects of SCG. By doing so, they can harness the technology's potential, ensure competitive edge, and contribute to the broader goal of advancing human health. Key Topics Covered: 1 Market Guides1.1 Situation Analysis1.2 Guide for Executives and Marketing Staff1.3 Guide for Investment Analysts and Management Consultants 2 Introduction and Market Definition2.1 What is Single Cell Genomics?2.2 SCG - Still Early Days2.3 Market Definition2.4 Methodology2.5 Sizing the Genome - Not What You Think 3 Single Cell Genomics - Guide to Technology3.1 Isolating Single Cells3.1.1 FACS3.1.2 LCM3.1.3 Micromanipulators3.1.4 Microfluidics3.2 Amplification3.2.1 WTA - Whole Transcriptome Amplification3.2.2 WGA - Whole Genome Amplification3.3 PCR3.4 NGS3.5 Microarray3.6 Digital Spatial Profiling (DSP) Technology 4 Industry Overview4.1 Academic Research Lab4.2 Diagnostic Test Developer4.3 Instrumentation Supplier4.4 Chemical/Reagent Supplier4.5 Pathology Supplier4.6 Independent Clinical Laboratory4.7 Public National/regional Laboratory4.8 Hospital Laboratory4.9 Physicians Office Lab (POLS)4.10 Audit Body4.11 Certification Body 5 Market Trends5.1 Factors Driving Growth5.1.1 Immuno-oncology5.1.2 Research Range5.1.3 Technology Maturity & Convergence5.1.4 Declining Costs5.2 Factors Limiting Growth5.2.1 Competition5.2.2 Instrument Integration5.2.3 Technology Shift5.2.4 Technology Limitations5.3 Technology Development5.3.1 Spatial Profiling5.3.2 Integration5.3.3 Big Data5.3.4 Kits and Commodities5.4 Instrumentation, Automation and Diagnostic Trends5.4.1 Traditional Automation and Centralization5.4.2 The New Automation, Decentralization and Point Of Care5.4.3 Instruments Key to Market Share5.4.4 Bioinformatics Plays a Role5.4.5 PCR Takes Command5.4.6 Next Generation Sequencing Fuels a Revolution5.4.7 NGS Impact on Pricing5.4.8 Whole Genome Sequencing, A Brave New World5.4.9 Companion Diagnostics Blurs Diagnosis and Treatment5.4.10 Shifting Role of Diagnostics 6 Single Cell Genomics Recent Developments6.1 Recent Developments - Importance and How to Use This Section6.1.1 Importance of These Developments6.1.2 How to Use This Section6.2 Scale Biosciences announces ScalePlex to simplify single cell genomics6.3 10x Genomics Launches 5,000-Plex Gene Panel for Xenium6.4 NIH researchers develop AI drug matching tool6.5 Curio Bioscience to Transform Single-Cell Sequencing Data into Spatial Context .. 1536.6 Factorial Biotechnologies Unveils Mosaic6.7 Deepcell and NVIDIA collaborate to advance AI in single cell research6.8 OWKIN Integrates 10x Genomics Spatial Omics and Single-Cell Technologies6.9 Beckman Coulter and 10x Genomics partner6.10 MGI and Xpress Genomics to Advance Single-cell RNA-Sequencing6.11 Single-Cell Sequencing Reveals Traits in Cereal Crops6.12 Single-cell Genomics meets Human Genetics6.13 Singular Genomics Launches Kits for Single Cell Sequencing6.14 Scale Biosciences Introduces Disruptive Single-Cell Profiling Solutions6.15 Singleron showcases latest single cell sequencing technology6.16 Oxford Nanopore to Make Single-cell Sequencing Accessible to Any Laboratory . 1686.17 Single-Cell RNA-seq Method Enables Profiling Live Cells6.18 Novogene Launches New Single-Cell Lab6.19 New DNA Atlas Provides Clues for Heart Disease Risk6.20 BioSkryb Genomics Launches ResolveOME6.21 Parse Biosciences Expands Single-Cell Product Line6.22 Massively Multiplexed Single-Cell In Situ Spatial Genomics Now in U.S. Market6.23 Pfizer Centralizes Single Cell Data on Seven Bridges System6.24 Consortium to Standardize Single-Cell Sequencing6.25 Scienion, Cellenion Enter Licensing Deal6.26 Immunai Acquires Swiss Bioinformatics Firm Nebion6.27 Startup MiCareo Targets Rare Cell Isolation Market6.28 Parse Biosciences Lowers Cost Barriers to Single-Cell Transcriptomics6.29 Deepcell Advancing Tech for Single-Cell Genomics6.30 10x Genomics Outlines 2021 Growth Plans6.31 Single-Cell Genomics Firm Analytical Biosciences Inks Deal with BioMap6.32 IsoPlexis Features Cheaper, More Flexible Single-Cell Proteomic Systems6.33 DNTR-Seq Combines WGS, Transcriptomics in Single Cells6.34 BitBiome Builds Single-Cell Bacterial Sequencing Business6.35 S2 Genomics Signs Distribution Agreements for Asia-Pacific6.36 Single-Cell COVID-19 Study Investigates Immune Hyperactivation6.37 Levitas Bio to Launch Magnetic Levitation Cell Separation Platform6.38 Single-Cell and Spatial Genomics6.39 Single-Cell Genomics6.40 Namocell, Takara Bio, HepaTx Partner on Single-Cell Genomics6.41 Vizgen Launches With $14M Series A Financing6.42 SeqWell Raises $9M in Series B Round 7 Profiles of Key Single Cell Genomics Companies7.1 10x Genomics, Inc.7.2 Admera Health, LLC7.3 Agilent7.4 Beckman Coulter Diagnostics (Danaher)7.5 Becton, Dickinson and Company7.6 Berkley Lights7.7 BGI Genomics Co. Ltd7.8 BioGenex7.9 Bio-Rad Laboratories, Inc7.10 BioSkryb Genomics7.11 Bitbiome7.12 Bruker7.13 Cell Microsystems7.14 Cellenion (BICO)7.15 CellSorter7.16 Cytek Biosciences7.17 Cytena7.18 Deepcell7.19 Dolomite Bio (Unchained Labs)7.20 Element Biosciences7.21 Epic Sciences7.22 Fluent Biosciences7.23 Fluxion Biosciences (Cell Microsystems)7.24 Honeycomb Biotechnologies7.25 Illumina7.26 Incell Dx7.27 Leica Biosystems7.28 Menarini Silicon Biosystems7.29 MGI7.30 Miltenyi Biotec7.31 Mission Bio7.32 Myllia Biotechnology7.33 Namocell7.34 NanoCellect Biotechnology7.35 Nanostring7.36 New England Biolabs, Inc.7.37 Novogene7.38 Oxford Nanopore Technologies7.39 Pacific Biosciences7.40 Parse Biosciences7.41 Partek7.42 Qiagen7.43 Revvity7.44 Roche Diagnostics7.45 S2 Genomics7.46 Scale Biosciences7.47 Singleron Biotechnologies7.48 Singular Genomics7.49 Singulomics7.50 Sony Biotechnology7.51 Standard BioTools7.52 Stemcell Technologies7.53 Takara Bio7.54 Thermo Fisher Scientific7.55 Ultima Genomics7.56 Vizgen7.57 Watchmaker Genomics 8 Single Cell Genomics Global Market Size8.1 Global Market Overview by Country8.2 Global Market Size by Analyte - Overview8.3 Global Market by Product - Overview8.4 Global Market by Workflow - Overview8.5 Global Market by End User - Overview8.6 Global Market by Application - Overview 9 Global Market by Analyte9.1 DNA Market9.2 RNA Market9.3 Epigenetic Market9.4 Proteomic Market9.5 Multiomics Market 10 Single Cell Genomics Market by Product10.1 Instrument Market10.2 Reagent Market10.3 Software & Other Market 11 Single Cell Genomics Market by Workflow11.1 Cell Isolation Market11.2 Sample Preparation Market11.3 Genomic Analysis Market 12 Single Cell Genomics Market by End User12.1 Research Market12.2 BioPharma Market12.3 Clinical Market 13 Global Market by Application13.1 Oncology Market13.2 Immunology Market13.3 Microbiology Market13.4 Cell Market13.5 Stem Cell Market13.6 Neurology Market 14 Appendices14.1 FDA Cancer Drug Approvals by Year14.2 Clinical Trials Started Historical14.3 Prevalence of Cancer Treatments For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
Forget This 15.3%-Yielding Stock. Consider These High-Yield Dividend Growers Instead.
AGNC Investment is a mortgage-focused real estate investment trust that offers a yield above 15% at recent prices. The mREIT offers a high yield because it's extremely sensitive to interest rate changes. A pair of real estate investment trusts that offer lower yields than AGNC Investment could outperform thanks to steadily growing dividend payouts. 10 stocks we like better than AGNC Investment Corp. › If you're looking for easy ways to pump up your passive income stream, you may have noticed some stocks out there offer dividend yields at double-digit percentages. One that gets a lot of attention is mortgage-focused real estate investment trust (mREIT) AGNC Investment (NASDAQ: AGNC). When markets opened on June 11, the stock was offering a 15.3% dividend yield. AGNC's yield is so high that you could receive your entire principal back in the form of monthly dividend payments in less than five years. Of course, that's only if the company can maintain its payout. Prologis (NYSE: PLD) and Realty Income (NYSE: O) have been offering dividend yields that aren't half as high as AGNC Investment's. Despite the lower payouts up front, there's a good chance these two will deliver more passive income over the long run. Income-seeking investors want consistency from their stocks, but not the sort of consistency they get from AGNC Investment. The mortgage REIT has lowered its dividend payout three times over the past 10 years. Instead of investing in real estate, AGNC Investment and its mREIT peers buy mortgage-backed securities (MBS). The mortgages in this mREIT's MBS portfolio are nearly always backed up by government agencies in the event of a default. Agency backing makes the portfolio somewhat resilient to economic downturns, but there isn't much the company can do about shifting interest rates. In a nutshell, mREITs borrow at relatively low short-term rates and use that capital to invest in MBS that pay higher rates over longer periods. It usually goes well, right up until the Federal Reserve rapidly alters interest rates. When interest rates rise, AGNC's short-term borrowing costs rise. At the same time, prices for existing securities in AGNC's MBS portfolio can plummet. AGNC Investment and mREITs, in general, employ a lot of leverage. When MBS values drop, the company can be forced to sell portions of its portfolio at fire-sale prices to boost liquidity and satisfy lenders. This is why, despite being a well-run business, AGNC is known for lowering its dividend payout, not raising it. Shares of Realty Income and Prologis almost never fall so low that their dividend yields reach a double-digit percentage. Long-term investors who bought shares of either of these stocks, though, have outperformed folks who bought AGNC Investment by a mile. Despite a global pandemic, relatively stable interest rates made the past decade a relatively good time to be an mREIT. However, even if we add up dividends received over the past 10 years, long-term AGNC investors realized a disappointing 65.6% total return during the 10-year period ended June 10. Realty Income's stock price rose by less than 30% over the same 10-year period. If we include Realty Income's steadily rising dividend payments, though, the stock produced a 101.3% total return. Prologis' focus on logistics real estate, which e-commerce businesses rely on, served it extremely well during the COVID-19 pandemic. The company raised its dividend payout by a whopping 152.5% during the decade ended June 10. Thanks to all those payout bumps, Prologis investors outperformed the S&P 500 (SNPINDEX: ^GSPC) with an outstanding 272.9% total return. Realty Income has been raising its dividend payout on a regular basis since it bought its first property in 1970. It became a publicly traded company in 1994, and its monthly dividend payment has risen every quarter since. Prologis doesn't have a dividend-raising streak as long as Realty Income's, but it hasn't had to lower its payout since 2009. Since 2013, its payout has grown every year like clockwork. At recent prices, it offers a 3.7% yield. Investors can confidently expect significant payout raises over the next several years from Prologis. With 95.2% of its 1.3 billion-square-foot logistics real estate portfolio rented out at the end of March, the net lease REIT won't have any trouble raising its dividend commitment in the quarters ahead. Management expects core funds from operations (FFO), a proxy for earnings used to evaluate REITs, to land in a range between $5.65 and $5.81 per share this year. That's more than enough to maintain and boost a dividend payout set at just $4.04 annually. Like Prologis, Realty Income is a net lease REIT that passes all the variable costs of building ownership to its tenants. With a retail portfolio full of convenience stores and other spaces that aren't particularly vulnerable to e-commerce, it boasted 98.5% occupancy at the end of March. At recent prices, Realty Income offers a 5.6% dividend yield that will almost certainly rise higher in the years ahead. The company expects adjusted FFO to land in a range between $4.22 to $4.28 per share this year. This is more than enough to maintain and raise a payout currently set at $3.22 per share. Prologis and Realty Income boast industry-leading credit ratings, which translates to lower borrowing costs than their peers. These REITs have been active for decades, but most companies still own most of the buildings they need to operate. With advantageous borrowing costs and a huge addressable market, these two leaders could continue their dividend-raising streaks for decades to come. Before you buy stock in AGNC Investment Corp., consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and AGNC Investment Corp. wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,102!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $882,344!* Now, it's worth noting Stock Advisor's total average return is 996% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Prologis and Realty Income. The Motley Fool recommends the following options: long January 2026 $90 calls on Prologis. The Motley Fool has a disclosure policy. Forget This 15.3%-Yielding Stock. Consider These High-Yield Dividend Growers Instead. was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
